Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7981205 | 0.84 | CRHR1 (0.35) | CRHR1KDM4EALDH1A1CASP1CASP7 | |
| SCHEMBL7071347 | 0.82 | CRHR1 (0.36) | CRHR1KDM4EALDH1A1CASP1CASP7 | |
| SCHEMBL7215494 | 0.80 | KDM4E (0.38) | CRHR1KDM4EALDH1A1CASP1CASP7 | |
| SCHEMBL7071736 | 0.80 | KDM4E (0.38) | CRHR1KDM4EALDH1A1CASP1CASP7 | |
| SCHEMBL7217519 | 0.76 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL7076053 | 0.74 | ADRB1 (0.39) | CRHR1KDM4EALDH1A1CASP1CASP7 | |
| SCHEMBL7215696 | 0.73 | CRHR1 (0.69) | CRHR1 | |
| SCHEMBL7076556 | 0.73 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL7075873 | 0.73 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL7217860 | 0.71 | CRHR1 (0.49) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105117-A1 | Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino[2,3-b]indole and 5,6,7,8-tetrahydro-9H-pyrimidino[4,5-b]indole derivatives: CRF1 specific ligands | NEUROGEN CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-6472402-B1 | Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives | NEUROGEN CORPORATION | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105117-A1 | Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino[2,3-b]indole and 5,6,7,8-tetrahydro-9H-pyrimidino[4,5-b]indole derivatives: CRF1 specific ligands | GPR119, CRHR1, IRS1 | CRHR1 2/4885KDM4E 3601/4885ALDH1A1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.